| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Hypera S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$28.78 |
| 52 Week High | R$46.84 |
| 52 Week Low | R$27.50 |
| Beta | 0.36 |
| 1 Month Change | -13.65% |
| 3 Month Change | -7.40% |
| 1 Year Change | -20.06% |
| 3 Year Change | -17.98% |
| 5 Year Change | 2.79% |
| Change since IPO | 244.67% |
Recent News & Updates
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 16
Is Hypera (BVMF:HYPE3) A Risky Investment?
Feb 21Recent updates
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 16Is Hypera (BVMF:HYPE3) A Risky Investment?
Feb 21Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Jan 09Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
Dec 22Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Nov 02Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Aug 27Is Hypera (BVMF:HYPE3) A Risky Investment?
Jul 21We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Apr 15With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
Feb 19We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
Jan 03Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
Oct 11Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Jul 19Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Jun 28Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Apr 14I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Mar 25Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Mar 04Shareholder Returns
| HYPE3 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 1.3% | 2.0% | 0.4% |
| 1Y | -20.1% | -15.4% | 13.9% |
Return vs Industry: HYPE3 underperformed the BR Pharmaceuticals industry which returned -14.6% over the past year.
Return vs Market: HYPE3 underperformed the BR Market which returned 14.9% over the past year.
Price Volatility
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: HYPE3 has not had significant price volatility in the past 3 months.
Volatility Over Time: HYPE3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 10,301 | Breno Pires de Oliveira | www.hyperapharma.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
Hypera S.A. Fundamentals Summary
| HYPE3 fundamental statistics | |
|---|---|
| Market cap | R$18.22b |
| Earnings (TTM) | R$1.65b |
| Revenue (TTM) | R$7.91b |
11.0x
P/E Ratio2.3x
P/S RatioIs HYPE3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYPE3 income statement (TTM) | |
|---|---|
| Revenue | R$7.91b |
| Cost of Revenue | R$2.92b |
| Gross Profit | R$5.00b |
| Other Expenses | R$3.35b |
| Earnings | R$1.65b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.60 |
| Gross Margin | 63.12% |
| Net Profit Margin | 20.83% |
| Debt/Equity Ratio | 86.5% |
How did HYPE3 perform over the long term?
See historical performance and comparison